Skip to content

Post LaUnch monitoring pretermS.

Monitoring of tolerance and safety in preterm infants during supplementation of protein in combination with human milk and/or preterm formula.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON24765
Enrollment
100
Registered
2013-03-01
Start date
2013-03-15
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preterm infants with extremely low birth weight (< 1000 g).

Interventions

None.

Sponsors

Danone Research - Centre for Specialised Nutrition
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Birth weight of < 1000 g; 2. Gestational age s 36 weeks; 3. Decision of the treating medical doctor to start using the Protein Supplement (not applicable for control group); 4. Written informed consent by parent(s)/legal guardian(s) (not applicable for control group).

Exclusion criteria

Exclusion criteria: 1. (Anticipated) transfer to another hospital within 2 weeks after start of full enteral feeding; 2. Major congenital disorders interfering with the protocol requirements as per investigator's clinical judgement; 3. Chromosomal aberrations interfering with the protocol requirements as per investigator's clinical judgement; 4. Systemic metabolic diseases; 5. Participation in any other studies involving investigational or marketed products interfering with the study conduct, as per investigator's clinical judgement.

Design outcomes

Primary

MeasureTime frame
1. Growth (gain in body weight, length and head circumference); 2. Gastrointestinal symptoms; 3. Serious Adverse Events (SAEs).

Secondary

MeasureTime frame
1. Parameters to assess digestive function in stool; 2. Parameters to assess digestive function in gastric aspirate.

Contacts

Public ContactSandra Helderman-Swart

PO Box 7005

sandra.helderman@danone.nl+31 (0)371 467800

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)